1. Home
  2. UCL vs LUNG Comparison

UCL vs LUNG Comparison

Compare UCL & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo uCloudlink Group Inc.

UCL

uCloudlink Group Inc.

HOLD

Current Price

$1.81

Market Cap

74.5M

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.56

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCL
LUNG
Founded
2014
1995
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Industrial Specialties
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.5M
63.6M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
UCL
LUNG
Price
$1.81
$2.56
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$6.81
AVG Volume (30 Days)
10.6K
1.1M
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
8.06
N/A
EPS
0.12
N/A
Revenue
$85,239,000.00
$91,664,000.00
Revenue This Year
N/A
$9.21
Revenue Next Year
$20.86
$5.03
P/E Ratio
$16.15
N/A
Revenue Growth
N/A
15.59
52 Week Low
$0.80
$1.31
52 Week High
$4.19
$9.37

Technical Indicators

Market Signals
Indicator
UCL
LUNG
Relative Strength Index (RSI) 37.11 70.34
Support Level $1.90 $1.96
Resistance Level $2.00 $2.66
Average True Range (ATR) 0.10 0.19
MACD -0.01 0.09
Stochastic Oscillator 22.47 88.07

Price Performance

Historical Comparison
UCL
LUNG

About UCL uCloudlink Group Inc.

Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: